Printer Friendly

Understand Unmet Needs In The Insomnia Market Based On Key Opinion Leader Comments.

DUBLIN, Ireland -- Research and Markets ( has announced the addition of "Pipeline Insight: Insomnia - Targeting The Sleep Maintenance Market" to their offering.

The launch of serotonin antagonists which are largely aimed at treating sleep maintenance is set to make a substantial impact on the insomnia market, which will increase in value across the seven major markets from $6.1 billion in 2006 to $7.7 billion in 2016.

Scope of this title:

Analysis of patient potential, unmet needs and clinical trial design in insomnia Overview of drugs in late- and early-stage clinical development; with analysis of key companies involved in the R&D pipeline Detailed profiles of key compounds in development for use in insomnia, with forecasts of drug revenues to 2016 Discussion of Sanofi-Aventis and Neurocrines strategies, and insight from key industry opinion leaders

Highlights of this title:

Serotonin receptor antagonists are the most prevalent drug clasWe predict that serotonin antagonist companies will be important players in the market in the future, led by Sanofi-Aventis eplivanserin. The majority of pipeline drugs are being investigated for sleep maintenance as opposed to sleep onset insomnia and there is a trend towards the development of drugs for the treatment of co-morbid disorders. In March 2007, Merck & Co. and Lundbeck discontinued development of their Phase III drug, gaboxadol, due to disappointing trial results. Although this is a considerable blow to Lundbeck, the reduction in competition is positive news for current and future insomnia market players.

Reasons to order your copy:

Understand unmet needs in the insomnia market based on key opinion leader comments Benchmark key late-stage insomnia compounds against current market leaders Assess the global (US, Japan, five major EU) sales forecasts of key late-stage pipeline drugs; and examine their clinical and commercial potential

For more information, visit

Source: Datamonitor
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jun 5, 2007
Previous Article:ClipBlast! Adds '1-Click Subscribe(TM)' to Third-Party Video Sites; New Way to Boost Loyalty, Traffic for Video Content Providers.
Next Article:Examine the Technological Factors Impacting the Russian Real Estate Sector.

Related Articles
MedPharm Receives Grant for Insomnia Nasal Spray; Leading Specialist Topical Company Developing Fast-Acting Nasal Sedative.
Sepracor Announces Presentation of LUNESTA(TM) Data at American Psychiatric Association Annual Meeting.
Newly Published Data Show Efficacy and Safety of LUNESTA(R) in Elderly Patients with Insomnia.
Data Show Sepracor's Lunesta(R) Improved Insomnia in Patients with Co-Existing Generalized Anxiety Disorder.
Results of Sepracor's LUNESTA(R) Next-Day Driving Study in Patients with Primary Insomnia Presented at American College of Neuropsychopharmacology...
Sepracor Announces Publication of Additional Data from Lunesta(R) Insomnia-Depression Study in the Journal of Clinical Sleep Medicine.
Merck & Co., Inc. and Lundbeck Discontinue Joint Development Program for Gaboxadol, an Investigational Compound for Insomnia.
Neurogen Proprietary Insomnia Compound Data Presented at American Psychiatric Association Annual Meeting.
Neurogen Proprietary Insomnia Compound Data to Be Presented at Associated Professional Sleep Societies Annual Meeting.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters